Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Vandana Singh

4606 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • Movers
  • News
  • Top Stories

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

By Vandana Singh
April 23, 3:00 PM
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams.

BNTX

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • News
  • Top Stories

Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape

By Vandana Singh
April 23, 2:55 PM
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia.

ANRO

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder

By Vandana Singh
April 23, 1:28 PM
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in sales.

NBIX

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Earnings
  • Equities
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Reiteration
  • Trading Ideas

Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic

By Vandana Singh
April 23, 12:44 PM
Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth.

DGX

Read More
2 minute read
  • Earnings
  • General
  • Guidance
  • Movers
  • News
  • Trading Ideas

JetBlue Airways Shares Witness Over 10% Drop On Disappointing Annual Outlook

By Vandana Singh
April 23, 11:29 AM
Despite a better-than-expected first-quarter EPS loss, JetBlue outlook remains bleak with declining sales and rising operating expenses.

JBLU

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Top Stories
  • Trading Ideas

Why Is Life Science-Focused Danaher Trading Higher On Tuesday?

By Vandana Singh
April 23, 10:13 AM
Danaher Corp's Q1 sales beat expectations despite a Y/Y decrease. Rainer Blair, CEO, highlights strong revenue, earnings, and cash flow. Biotech sales dip, while life sciences and diagnostics segments see slight growth. Q2 sales are expected to decline.

DHR

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Top Stories

FDA Approves ImmunityBio’s Bladder Cancer Drug, Stock Rallies

By Vandana Singh
April 23, 9:54 AM
FDA approves ImmunityBio's Anktiva plus Bacillus Calmette-Guérin for BCG-unresponsive non-muscle invasive bladder cancer. Anktiva shows promising complete response rates and duration exceeding 24 months.

IBRX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Trading Ideas

FDA Rejects Approval Of Abeona Therapeutics’ Skin Disorder Treatment, Shares Sink

By Vandana Singh
April 23, 9:43 AM
Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Manufacturing and Controls requirements.

ABEO

Read More
2 minute read
  • Biotech
  • Earnings
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Top Stories

Novartis Stock Gains On European Drugmaker’s Q1 Earnings Surprise, Lifts Annual Outlook

By Vandana Singh
April 23, 8:25 AM
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth.

BMY

Read More
2 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Legal
  • Movers
  • News
  • Trading Ideas

US Supreme Court Declines To Hear Vanda Pharmaceuticals’ Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz

By Vandana Singh
April 22, 2:37 PM
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."

TEVA

Posts pagination

Previous 1 … 32 33 34 … 461 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service